Healthcare costs of COPD in Italian referral centres: A prospective study

Respiratory Medicine

Volumn 101, Issue 11, 2007, Pages 2312-2320

  Koleva, Daniela ^a   Motterlini, Nicola ^a   Banfi, Paolo ^b   Garattini, Livio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b AO Mellini   (Italy)

Author keywords

COPD; Costs; Italy; Severity

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; EXPECTORANT AGENT; METHYLXANTHINE DERIVATIVE; MUCOLYTIC AGENT; VACCINE;

ADULT; AGE; AGED; ARTICLE; BREATHING EXERCISE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OXYGEN THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; ITALY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REFERRAL AND CONSULTATION; STATE MEDICINE;

EID: 34848833576     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2007.06.020     Document Type: Article

References (27)

1. National Heart, Lung and Blood Institute (NHLBI)/World Health Organization (WHO) workshop report. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Pulmonary Disease. Bethesda: National Heart, Lung and Blood Institute, [Revised Edition 2006; NIH publication no. 2701:1-100].
2. Sutherland E.R., and Cherniack R.M. Management of chronic obstructive pulmonary disease. N Engl J Med 350 (2004) 2689-2697
3. Masa J.F., Sobradillo V., Villasante C., et al. Costs of chronic obstructive pulmonary disease in Spain: estimation from a population-based study. Arch Bronchopneumol 40 (2004) 72-79
4. Detournay B., Pribil C., Fournier M., et al. The SCOPE Study: health-care consumption related to patients with chronic obstructive pulmonary disease in France. Value Health 7 2 (2004) 168-174
5. O'Brien J.A., Ward A.J., Jones M.K.C., McMillan C., and Lordan N. Utilization of health care services by patients with chronic obstructive pulmonary disease. Resp Med 97 Suppl.A (2003) S53-S58
6. Hilleman D.E., Dewan N., Malesker M., and Friedman M. Pharmacoeconomic evaluation of COPD. Chest 118 (2000) 1278-1285
7. Jansson S.A., Andersson F., Borg S., Ericsson A., Jönsson E., and Lundbäck B. Costs of COPD in Sweden according to disease severity. Chest 122 (2002) 1994-2002
8. Miravitlles M., Murio C., Guerrero T., and Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 123 (2003) 784-791
9. Dal Negro R., Rossi A., and Cerveri I. The burden of COPD in Italy: results from the confronting COPD survey. Resp Med 97 Suppl. C (2003) S43-S50
10. Dal Negro R., Berto P., Tornella S., Quareni L., and on behalf of GOLD Study Group. Cost-of-illness of lung disease in the Tri Veneto Region, Italy: the GOLD Study. Monaldi Arch Chest Dis 57 (2002) 1-7
11. Oostenbrink J.B., and Rutten-van Mölken M.P. Resource use and risk factors in high-cost exacerbations of COPD. Resp Med 98 9 (2004) 883-891
12. Andersson F., Borg S., Jansson S.A., et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Resp Med 96 9 (2002) 700-708
13. Wilson L., Devine E.B., and So K. Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Resp Med 94 (2000) 204-213
14. Miravitlles M., Murio C., Guerriero T., Gisbert R., and for the DAFNE Study Group. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 121 5 (2002) 1449-1455
15. Sullivan S.D., Ramsey S.D., and Lee T.A. The economic burden of COPD. Chest 117 2 Suppl. (2000) 5S-9S
16. France G., and Taroni F. The evolution of health-policy making in Italy. J Health Polit Policy Law 30 1-2 (2005) 169-187
17. Taroni F. DRG/ROD e nuovo sistema di finanziamento degli ospedali (1996), Il Pensiero Scientifico Editore, Rome
18. Ministero della salute: 〈http://www.ministerosalute.it〉.
19. Motterlini N., Koleva D., and Garattini L e Gruppo di Studio Progetto B.I.C. I costi della BPCO in Italia: l'analisi retrospettiva dello studio BIC. Economia & Politica del Farmaco 4 (2005) 20-28
20. Motterlini N., and Garattini L. I costi di struttura dei reparti di pneumologia in Italia. FarmacoEconomia News 3 (2007) 3-7
21. Garattini L., Giuliani G., and Pagano E. A model for calculating costs of hospital wards: an Italian experience. J Manage Med 13 (1999) 71-82
22. Drummond M.F., O'Brien B.J., Stoddart G.L., and Torrance G.W. Methods for the economic evaluation of health care programmes (1997), Oxford University Press, Oxford
23. Garattini L., Cornago D., and Tediosi F. A comparative analysis of domiciliary oxygen therapy in five European countries. Health policy 58 (2001) 133-149
24. Garattini L., and Cornago D. Ossigenoterapia a lungo termine: modalità di acquisto e distribuzione in Italia. Economia & Politica del Farmaco 2 (2004) 29-36
25. Carpenter J., and Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med 19 (2000) 1141-1164
26. Sculpher M.J., Pang F.S., Manca A., et al. Generalisability in economic evaluation studies in healthcare: a review and studies. Health Technol Assess 8 49 (2004) 1-192
27. Boulenger S., Nixon J., Drummond M., Ulmann P., Rice S., and de Pouvourville G. Can economic evaluations be made more transferable?. Eur J Health Econom 6 (2005) 334-346